rapid eating triggers more severe GLP-1 gastric signals
-Six months of needle therapy, Roche/Alnylam's new SiRNA antihypertensive drug is planned to be included in breakthrough therapies On June 2, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Roche's Zilebesiran is intended to be included as a breakthrough therapy for adult hypertensive patients with cardiovascular disease or high risk of cardiovascular disease, in order to reduce the risk of cardiovascular death, non fatal myocardial infarction, non fatal stroke, and heart failure events (hospitalization or emergency treatment for heart failure)
Methionine keeps auditory hair cells as well as auditory neurons safe from ototoxicity, particularly from aminoglycosides, ionic platinum compounds, and cisplatin
In conclusion, while there is some concern about the potential link between semaglutide and AFib, the overall risk appears to be low
R.EarnestA.ShawK.HareJ
This improvement in metabolic and reproductive health may offset any theoretical concerns, making semaglutide a net positive for fertility planning when used strategically before conception attempts
